• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients.

Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients.

Details
Files
DOI
10.48620/97158
Publisher DOI
10.1038/s41598-026-47642-z
PubMed ID
41998023
Abstract
In pediatric cancer patients, platinum-induced sensory hearing loss (SHL) manifests in bilateral, symmetrical loss of outer hair cells and starts at a frequency range up to 10 kHz. Hearing loss has a significant impact on education, social integration and personality development in childhood cancer survivors. Early reliable detection of hearing loss may prompt attending oncologists to change chemotherapy if a less ototoxic therapeutic alternative is available. Pediatric cancer patients (2-19 years) receiving cisplatin-, carboplatin- or vincristine-containing regimens were eligible. Ultra-high frequency pure tone audiometry (PTA) and ultra-high frequency DPOAE measurements (up to 16 kHz) were compared. A total of 153 examinations were performed in 83 consecutive patients. While only 60 PTAs yielded reliable results, 153 DPOAE examinations up to 16 kHz were informative. Significant findings were observed between 10 and 16 kHz in both PTA and DPOAE assessments. In the cisplatin group, we found a significant reduction in DPOAE levels from 13 to 16 kHz, as well as a significant increase in DPOAE levels at 2.5 kHz and 3 kHz. Treatment with VCR and carboplatin did not result in substantial SHL. Hearing measurements up to 16 kHz can reveal an early ototoxic effect. In pediatric cancer patients, DPOAE measurement (up to 16 kHz) is more feasible and reliable (compared to PTA) and can detect SHL in ultra-high frequencies (10-16 kHz) at an earlier time point.
Date Issued
2026-04-18
Publication Type
Article
Subjects
Carboplatin
•
Cisplatin
•
Normal hearing
•
Otoacoustic emissions
•
Ototoxicity
•
Outer hair cells
•
Pure tone audiometry
•
Sensory hearing loss
•
Vincristine
Language(s)
en
Author(s)
Hecker, Dietmar J
Remke, Marc K H
Linxweiler, Maximilian
Furtwängler, Rhoikos  
Department of Paediatrics  
Akrasu, Yeliz
Schöndorf, Dominik
Graf, Norbert
Krieter, Dorothée
Oberkircher, Nadine
Schick, Bernhard
Bozzato, Alessandro
Simon, Arne
Additional Credits
Department of Paediatrics  
Journal
Scientific Reports
Publisher
Nature Research
ISSN
2045-2322
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify